Amylin Pharmaceuticals and Eli Lilly and Co. publicly disclosed the deaths of four patients using Byetta to address concerns about the diabetes drug's safety. An FDA announcement last week mentioned six cases -- including two deaths -- of acute pancreatitis linked to the treatment. But the companies said they had told the FDA about the four deaths, which are in addition to the six cases reported.

Related Summaries